Photo from Guilherme Nader Marta/X
Mar 13, 2024, 23:46
Guilherme Nader Marta: Our meta-analysis looking at the prognostic value of ctDNA in early breast cancer is now out at ESMO Open
Guilherme Nader Marta, Oncology Fellow at Jules Bordet Institute, shared on LinkedIn:
“Our meta-analysis looking at the prognostic value of ctDNA in early breast cancer is now out at ESMO Open.
ctDNA is a strong prognostic factor in early breast cancer and its detection was associated with increased risk of recurrence and death. The association with worse outcomes was stronger when ctDNA was detected after treatment and by primary tumor-informed assays.
The mean lead time from ctDNA detection to overt recurrence was ~11 months.
ctDNA detection specificity for breast cancer recurrence was high (range 0.7 to 1.0) but sensitivity was lower (range 0.3 to 0.7).
Check it out.”
Source: Guilherme Nader Marta/LinkedIn
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Mar 29, 2025, 04:16
Mar 28, 2025, 20:11
Mar 28, 2025, 19:58
Mar 28, 2025, 19:38